title: Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis.
abstract: We evaluated 148 patients with allergic conjunctivitis in a double-masked, paired comparison clinical trial comparing ketorolac 0.5% ophthalmic solution with vehicle. Patients received one drop of each study medication in preassigned eyes, four times a day, for seven days. Both treatments showed significant changes from baseline in the signs and symptoms associated with allergic conjunctivitis. Evaluations at the final visit (day 7 or 8) showed that ketorolac-treated eyes had a significant treatment response when compared to vehicle-treated eyes for conjunctival inflammation (p = 0.010), ocular itching (p = 0.006), swollen eyes (p = 0.002), discharge/tearing (p = 0.021), foreign body sensation (p = 0.035), and conjunctival injection (p = 0.016). Mean scores evaluating the overall therapeutic effect of the study treatments at the completion of the study were higher for ketorolac-treated eyes than for vehicle-treated eyes as rated by investigators (p = 0.004) and study patients (p < 0.001). Results of this study confirmed the trends of a previous study showing that ketorolac 0.5% ophthalmic solution applied topically is an effective therapy for allergic conjunctivitis.
authors.affiliation: Division of Allergy and Immunology, University of Iowa, Iowa City.
authors.forename: Z
authors.initials: Z
authors.lastname: Ballas
authors.forename: M
authors.initials: M
authors.lastname: Blumenthal
authors.forename: D G
authors.initials: DG
authors.lastname: Tinkelman
authors.forename: R
authors.initials: R
authors.lastname: Kriz
authors.forename: G
authors.initials: G
authors.lastname: Rupp
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D020911:Ketorolac Tromethamine; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D014677:Pharmaceutical Vehicles; D014046:Tolmetin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014325:Tromethamine / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D014677:Pharmaceutical Vehicles; D014325:Tromethamine; D020911:Ketorolac Tromethamine; D014046:Tolmetin